390 related articles for article (PubMed ID: 21366636)
1. Review article: loss of response to anti-TNF treatments in Crohn's disease.
Ben-Horin S; Chowers Y
Aliment Pharmacol Ther; 2011 May; 33(9):987-95. PubMed ID: 21366636
[TBL] [Abstract][Full Text] [Related]
2. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.
Danese S; Fiorino G; Reinisch W
Aliment Pharmacol Ther; 2011 Jul; 34(1):1-10. PubMed ID: 21539588
[TBL] [Abstract][Full Text] [Related]
3. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments.
Sandborn WJ
Rev Gastroenterol Disord; 2007; 7 Suppl 2():S23-35. PubMed ID: 17392636
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.
Wilhelm SM; Taylor JD; Osiecki LL; Kale-Pradhan PB
Ann Pharmacother; 2006 Oct; 40(10):1804-13. PubMed ID: 16985094
[TBL] [Abstract][Full Text] [Related]
6. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease.
Bruining DH; Sandborn WJ
Clin Gastroenterol Hepatol; 2011 May; 9(5):395-9. PubMed ID: 21277392
[TBL] [Abstract][Full Text] [Related]
7. [Anti-TNF therapy and Crohn's disease].
Peyrin-Biroulet L
Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):478-81. PubMed ID: 18439777
[No Abstract] [Full Text] [Related]
8. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
9. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis.
Epstein D; Watermeyer G; Kirsch R
Aliment Pharmacol Ther; 2007 Jun; 25(12):1373-88. PubMed ID: 17539977
[TBL] [Abstract][Full Text] [Related]
10. Medical therapy for refractory pediatric Crohn's disease.
Faubion WA; Bousvaros A
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1199-213. PubMed ID: 16872913
[TBL] [Abstract][Full Text] [Related]
11. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.
Peyrin-Biroulet L; Colombel JF; Sandborn WJ
Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1139. PubMed ID: 19465159
[No Abstract] [Full Text] [Related]
12. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
13. [Biological compounds in the treatment of Crohn's disease].
Dinari G
Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
[No Abstract] [Full Text] [Related]
14. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
Desai AA; Marks DJ
Expert Rev Clin Immunol; 2010 Sep; 6(5):695-9. PubMed ID: 20828275
[No Abstract] [Full Text] [Related]
15. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
Sorrentino D; Terrosu G; Vadalà S; Avellini C
Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
[No Abstract] [Full Text] [Related]
16. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of colitis ulcerosa and Crohn's disease].
Kovács A
Orv Hetil; 2006 Apr; 147(16):755-8. PubMed ID: 16711262
[No Abstract] [Full Text] [Related]
18. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease - A controlled clinical trial.
Krebs S; Omer TN; Omer B
Phytomedicine; 2010 Apr; 17(5):305-9. PubMed ID: 19962291
[TBL] [Abstract][Full Text] [Related]
19. TNF-alpha antagonists: benefits beyond remission.
Mahadevan U
Rev Gastroenterol Disord; 2007; 7 Suppl 1():S13-9. PubMed ID: 17392633
[TBL] [Abstract][Full Text] [Related]
20. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.
Danese S; Colombel JF; Reinisch W; Rutgeerts PJ
Aliment Pharmacol Ther; 2011 Apr; 33(8):857-69. PubMed ID: 21320139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
